This group of diseases is characterized by systemic or intrarenal aggregation of platelets, thrombocytopenia, and mechanical injury to erythrocytes.
Along with the well known routine laboratory parameters, measurement of factor H and metalloproteinases namely ADAMTS13 is recommended.
The pathogenetic link is the occlusion of microvessels by microthrombi. The resulting insufficient perfusion is responsible for the organ specific symptoms.
|Hereditary kidney diseases|
|Congenital abnormalities of the kidney and urinary tract|
|Cystic kidney disease|
|Disorders of tubular solute transport|
|Hereditary glomerular disease|
|Hereditary metabolic kidney disease|
|Hereditary renal tumors|
|Interstitial kidney disease|
|Kidney disease appearing as endocrinological disorders|
|Methylmalonic aciduria and homocystinuria cblC|
|Methylmalonic aciduria and homocystinuria cblD|
|Methylmalonic aciduria type mut|
|Poor response to Eculizumab|
|Thrombotic Thrombocytopenic Purpura|
Nürnberger J et al. (2009) Eculizumab for atypical hemolytic-uremic syndrome.
McCrae KR et al. (2001) Platelets: an update on diagnosis and management of thrombocytopenic disorders.
None (2002) Thrombotic microangiopathies.
Shah NT et al. (2003) Controversies in differentiating thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.
Wikipedia articleWikipedia EN (Thrombotic_microangiopathy)